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Dietary lipids fuel GPX4-restricted enteritis
resembling Crohn’s disease
Lisa Mayr1,13, Felix Grabherr1,13, Julian Schwärzler1, Isabelle Reitmeier1, Felix Sommer 2, Thomas Gehmacher1,
Lukas Niederreiter1, Gui-Wei He3, Barbara Ruder3, Kai T. R. Kunz1, Piotr Tymoszuk 4, Richard Hilbe4,5,
David Haschka4, Clemens Feistritzer6, Romana R. Gerner1, Barbara Enrich1, Nicole Przysiecki1,7,
Markus Seifert4,5, Markus A. Keller 8, Georg Oberhuber9, Susanne Sprung10, Qitao Ran11, Robert Koch1,
Maria Effenberger1, Ivan Tancevski4, Heinz Zoller1, Alexander R. Moschen 1,7, Günter Weiss 4,5,
Christoph Becker3, Philip Rosenstiel2, Arthur Kaser12, Herbert Tilg1 & Timon E. Adolph1✉
The increased incidence of inflammatory bowel disease (IBD) has become a global phe-
nomenon that could be related to adoption of a Western life-style. Westernization of dietary
habits is partly characterized by enrichment with the ω-6 polyunsaturated fatty acid (PUFA)
arachidonic acid (AA), which entails risk for developing IBD. Glutathione peroxidase 4
(GPX4) protects against lipid peroxidation (LPO) and cell death termed ferroptosis. We
report that small intestinal epithelial cells (IECs) in Crohn’s disease (CD) exhibit impaired
GPX4 activity and signs of LPO. PUFAs and specifically AA trigger a cytokine response of
IECs which is restricted by GPX4. While GPX4 does not control AA metabolism, cytokine
production is governed by similar mechanisms as ferroptosis. A PUFA-enriched Western diet
triggers focal granuloma-like neutrophilic enteritis in mice that lack one allele of Gpx4 in IECs.
Our study identifies dietary PUFAs as a trigger of GPX4-restricted mucosal inflammation
phenocopying aspects of human CD.
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Oxidation of biolipids, referred to as lipid peroxidation(LPO), is controlled by enzymatic (e.g. lipoxygenase-mediated) and non-enzymatic (e.g. fenton-type) reactions
that particularly affect polyunsaturated fatty acids (PUFAs)
within biological membranes1–3. LPO impairs cellular functions
partly by forming cytotoxic protein adducts or damage to cellular
membranes4. Compensation is provided by glutathione peroxidase
4 (GPX4), the only selenoprotein that catalyzes the reduction of
oxidized biolipids1,3,5. Deletion of both Gpx4 alleles in mice or
pharmacologic GPX4 inhibition in cells induces a distinct regulated
form of iron-dependent cell death termed ferroptosis1. Ferrop-
tosis requires acyl-CoA synthetase long-chain family member 4
(ACSL4)-mediated membrane enrichment of the ω-6 PUFA ara-
chidonic acid (AA), which is prone to oxidation2,6,7. Deletion of
both alleles of Gpx4 culminates in organ injury of the kidney, brain,
and skin, which is conceivably elicited or modulated by immune
responses3,8–11. While studies have identified key regulators of
GPX4-restricted LPO and cellular demise1,2,6,12–14, mechanism(s)
of concurrent inflammatory responses remain elusive.
Inflammatory bowel diseases (IBDs) and specifically Crohn’s
disease (CD) are characterized by chronic remittent intestinal
inflammation that arises from complex interactions between
environmental factors (e.g. diet) in a genetically susceptible
host15. However, plausible examples to support this assumption
remain scarce16–18. Notably, the increase in incidence of IBD
parallels the increase in dietary intake of ω-6 PUFAs such as AA,
which is a major component of a Western diet and contained in
meat and eggs19. Although AA intake entails a risk for developing
IBD20 and accumulates in the inflamed mucosa of IBD patients21,
the impact of AA and PUFA metabolism on intestinal inflam-
mation remains controversial22.
Given the genetic association between GPX4 and CD23 and
reports of GPX4-restricted AA oxidation in biological mem-
branes2,6, we set out to study the role of intestinal epithelial GPX4
in controlling gut homeostasis24,25. We find that CD epithelium
exhibits reduced GPX4 activity and features of LPO. In intestinal
epithelial cells (IECs) with reduced GPX4 activity, PUFAs and
specifically AA induce the release of interleukin 6 (IL-6) and
chemokine (C-X-C motif) ligand 1 (CXCL1) which is governed by
iron availability, lipoxygenase-mediated LPO and Acsl4. Mice that
are exposed to a PUFA-enriched Western diet and that lack one
Gpx4 allele in IECs (Gpx4+/−IEC), but not wild-type (WT) mice,
display signs of epithelial LPO and focal neutrophilic enteritis with
granuloma-like accumulation of inflammatory cells. Oral AA
exposure evokes neutrophilic inflammation in the small intestine of
iron-primed Gpx4+/−IEC mice. Enteritis in both models can be
ameliorated by LPO scavenging. As such, our study exemplifies
how PUFAs in a Western diet pose a risk for developing CD.
Results
Impaired epithelial GPX4 activity features CD. To investigate a
role of reduced GPX4 activity and LPO in human IBD, we analyzed
biopsy-derived IEC-enriched specimens from the lesional and non-
lesional mucosa of CD and ulcerative colitis (UC) patients with
active disease. Non-IBD patients who underwent screening colo-
noscopy and lacked demonstrable intestinal disease by endoscopic
and histologic means served as healthy controls (HC). Clinical
characteristics of this cohort are summarized in Table 1. IECs
derived from the lesional small intestinal mucosa of CD patients
exhibited decreased expression of GPX4, which was paralleled by
decreased enzymatic activity (Fig. 1a-e and Supplementary Fig. 1A).
In contrast, colonic GPX4 expression and activity in UC patients
was indistinguishable from that in healthy controls (Fig. 1f, g),
similar to GPX4 expression in colonic CD (Fig. 1f). In line with this,
IECs of the lesional small intestinal mucosa of CD patients exhib-
ited signs of LPO indicated by 4-HNE adducts (Fig. 1h), which was
similarly notable in small intestinal epithelial organoids retrieved
from lesional mucosa of CD patients (Supplementary Fig. 1B).
PUFAs evoke an inflammatory response of Gpx4-deficient
IECs. To analyze the role of GPX4 in IECs, we first generated
Gpx4−/− small intestinal epithelial MODE-K cells by CRISPR Cas9
editing of exon 126, which induced IEC death and thus prevented
further studies (Supplementary Fig. 1C, D). To assess the con-
sequences of reduced (but not completely abrogated) GPX4 activity
in IECs, we silenced MODE-K cells with Gpx4 small-interfering
RNA (siGpx4). siGpx4 silencing impaired Gpx4 expression and
enzymatic activity by ~75% (Supplementary Fig. 1E-G). As oxi-
dation of PUFAs and specifically AA is restricted by GPX42, we, in
a first step, tested the impact of reduced GPX4 activity and AA
exposure on intestinal epithelial LPO. Indeed, the ω-6 PUFA AA
deteriorated LPO in Gpx4-deficient IECs (Fig. 2a and Supple-
mentary Fig. 1H). Importantly, AA induced the expression of IL-6
and CXCL1 in siGpx4 IECs, but not in control IECs (Fig. 2b–e).
Similarly, ω-3 and ω-6 PUFAs, i.e. stearidonic acid (SDA), doc-
osahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and doc-
osapentaenoic acid (DPA), induced LPO (Fig. 2f) and IL-6 and
CXCL1 production (Fig. 2g, h) in siGpx4, but not in siCtrl IECs.
The saturated long-chain fatty acid palmitic acid (PA) induced
LPO, IL-6 and CXCL1 responses to a similar extent in siGpx4 and
siCtrl IECs (Fig. 2f-h). Monounsaturated fatty acids such as pal-
mitoleic acid (POA) and oleic acid (OA) did not impact LPO or
cytokine production in siGpx4 IECs (Fig. 2f-h). Other pro-
inflammatory stimuli such as TNFα or IL-1β evoked cytokine
responses from siGpx4 IECs that were comparable to siCtrl IECs
(Fig. 2i, j). As such, PUFAs particularly elicited LPO and a cytokine
response in Gpx4-deficient IECs.
A PUFA-enriched Western diet induces enteritis in Gpx4+/−IEC
mice. Next, we set out to study the impact of PUFAs on intestinal
inflammation in GPX4-deficient mice. We were unable to
retrieve homozygous Gpx4flox/flox;Villin-Cre+/− (Gpx4−/−IEC)
mice as the offspring died in utero. However, 11% Gpx4−/−IEC
pups were born when the diet of the mothers during gestation
Table 1 Patient characteristics.
HC CD UC
Total N 21 16 12
male/female (%) 43/57 50/50 75/25
Age (years) 51.62 ± 12.1 39.06 ± 14.4 40.38 ± 13.7
Body mass index (kg/m²) 28.56 ± 6.17 24.06 ± 5.81 23.70 ± 3.48
MAYO Score N/A N/A 4.75 ± 0.69
Harvey–Bradshaw Index N/A 4,67 ± 0.52 N/A
CRP (mg/dl) N/A 0.55 ± 0.04 0.59 ± 0.14
HC healthy control, CD Crohn’s disease, UC ulcerative colitis, N patient numbers, CRP C-reactive protein.
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was supplemented with α-tocopherol (Supplementary Table 1,
Supplementary Fig. 2A, B). Gpx4−/−IEC pups from α-tocopherol
treated mothers had lower weight at birth but regained weight at
7 weeks of age (Supplementary Fig. 2C–F), with a mucosa that
was morphologically comparable to WT littermates (Supple-
mentary Fig. 2G, H). For further studies, we utilised Gpx4flox/wt;
Villin-Cre+/− (Gpx4+/−IEC) mice27,28, which specifically deleted
one Gpx4 allele in the intestinal epithelium and resulted in a
~50% reduction of mRNA and protein levels in small and large
intestinal IECs (Supplementary Fig. 3A, B). Gpx4+/−IEC mice
were viable, born at Mendelian ratio and exhibited a mucosal
appearance indistinguishable from that of WT littermates
(Fig. 3a and Supplementary Fig. 3C). LPO, IEC death and pro-
liferation were comparable between Gpx4+/−IEC and WT mice
(Supplementary Fig. 3D–H). Notably, Gpx4+/−IEC mice were
susceptible to colonic inflammation induced by dextran sodium
sulfate (DSS) (Supplementary Fig. 3I–M), as previously observed
in mice with myeloid-specific deletion of Gpx429.
In a next step, we orally challenged Gpx4+/−IEC and WT mice
with a Western-style diet (ssniff TD88137) enriched with or without
10% fish oil (containing ω-3 and ω-6 PUFAs, Supplementary
Table 2) for 3 months. As expected, WT mice were unaffected by a
low-fat control diet (LFD), a Western diet (WD) or a PUFA-
enriched Western diet (PUFA WD) (Fig. 3b and Supplementary
Fig. 4A). In contrast, a PUFA-enriched Western diet evoked patchy
small intestinal inflammation in Gpx4+/−IEC mice, while the colon
was unaffected. Specifically, PUFA WD-fed Gpx4+/−IEC mice
displayed mucosal to submucosal infiltration of neutrophil granu-
locytes and mononuclear cells, crypt hyperplasia, epithelial injury
and granuloma-like accumulation of inflammatory cells resembling
some aspects of small intestinal CD (Fig. 3b–d and Supplementary
Fig. 4B). Intestinal inflammation in PUFA WD-fed Gpx4+/−IEC
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Fig. 1 Reduced GPX4 activity and LPO localize to IECs in CD patients. a Relative GPX4 expression in the macroscopically inflamed (lesional, L) and
macroscopically non-inflamed (non-lesional, NL) small intestinal mucosa of CD patients determined by qPCR and compared to healthy controls (HC). Each
dot represents one patient (n= 9 for HC, n= 11 for CD-L, and n= 10 for CD-NL). *P= 0.0167. b, c Representative GPX4 immunoblot of IEC-enriched
fractions from biopsies taken from the ileum of CD patients and HC (b), with densitometry relative to GAPDH shown in (c). Each dot represents one
patient (n= 7 patients per group). *P= 0.0265. d Relative GPX4 enzymatic activity of epithelial-enriched fractions derived from the lesional (L) and non-
lesional (NL) mucosa of the small intestine of CD patients as compared to HC. Each dot represents one patient (n= 19 for HC, n= 6 for CD-L, and n= 5 for
CD-NL). ***P < 0.001, **P < 0.01. e Representative GPX4 immunoreactivity (brown) determined in the lesional small intestinal sections of CD patients as
compared to HC (n= 7). f Relative GPX4 expression in the macroscopically inflamed (lesional, L) and non-inflamed (non-lesional, NL) mucosa of the large
intestine of CD patients and UC patients as compared to HC. Each dot represents one patient (n= 7 for HC, n= 9 CD-L, n= 10 for CD-NL, n= 12 for UC-L
and n= 7 for UC-NL). g Quantification of GPX4 enzymatic activity in lesional and non-lesional IEC-enriched fractions from the large intestine of UC as
compared to HC. Each dot represents one patient (n= 15 for HC, n= 4 for UC-L, and n= 5 for UC-NL). h 4-HNE immunoreactivity (brown) in HC and
small intestinal lesional sections of CD patients, indicative for LPO. L, luminal-oriented side (n= 3 patients per group). Scale bars indicate 25 µm (e) and
50 µm (h). For panel (a), (c), (d), (f), and (g) data are presented as mean±SEM. One-way ANOVA with Bonferroni’s multiple comparison test. Source data
are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15646-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1775 | https://doi.org/10.1038/s41467-020-15646-6 | www.nature.com/naturecommunications 3
Time [hours]
R
el
at
iv
e 
Il-
6
e
xp
re
ss
io
n
0 4 8 12 16 20 24
0
0.5
1.0
1.5
2.0
2.5 siCtrl
siGpx4
***
Time [hours]
0 4 8 12 16 20 24
0
1
2
3
4
siCtrl
siGpx4
R
el
at
iv
e 
Cx
cl1
e
xp
re
ss
io
n
 
**
db
0
20
40
60
a
*
 
BO
DI
PY
59
1+
 
IE
Cs
 [%
]
 
Ve
hic
le AA
siCtrl
siGpx4
e
CX
CL
1 
[pg
/m
l]
**
0
5000
10000
15000
20000
25000
30000
Ve
hic
le AA
0
2000
4000
6000
8000c
IL
-6
 [p
g/m
l]
Ve
hic
le AA
***
f ***
 
BO
DI
PY
59
1+
 
IE
Cs
 [%
]
 
Ve
hic
le
EP
APA PO
A OA
0
20
40
60
80
SD
A
DP
A
DH
A
*** *** **
h
CX
CL
1 
[pg
/m
l]
0
5000
10000
15000
20000
25000
Ve
hic
le
EP
APA PO
A OA SD
A
DP
A
DH
A
*** *** *** ***
IL
-6
 [p
g/m
l]
g
** ** ** ***
0
500
1000
1500
2000
2500
Ve
hic
le
EP
APA PO
A OA SD
A
DP
A
DH
A
IL
-6
 [p
g/m
l]
Ve
hic
le
TN
Fα
IL-
1β
0
20000
40000
60000
80000
0
10000
20000
30000
40000
CX
CL
1 
[pg
/m
l]
Ve
hic
le
TN
Fα
IL-
1β
i j
Fig. 2 PUFAs trigger epithelial LPO and an inflammatory response restricted by GPX4. a LPO quantification by flow cytometry of BODIPY581/591 C11+-
labeled IECs stimulated with arachidonic acid (AA) for 24 h (n= 6 biologically independent experiments). *P= 0.0183. b, c Quantification of IL-6
expression from siGpx4 and siCtrl IECs over a course of AA stimulation determined by qPCR (n= 4 biologically independent experiments), ***P<0.001 (b),
and after 24 h by ELISA (n= 12 for vehicle and n= 24 for AA biologically independent experiments). ***P < 0.001 (c). d, e Quantification of CXCL1
expression from siGpx4 and siCtrl IECs over a course of AA stimulation determined by qPCR (n= 3 biologically independent experiments). **P= 0.001 (d)
and after 24 h by ELISA (n= 12 for vehicle and n= 24 for AA), **P= 0.0031 (e). f LPO quantification by flow cytometry of BODIPY581/591 C11+-labeled
IECs stimulated with the saturated fatty acid palmitic acid (PA), monounsaturated fatty acids palmitoleic acid (POA) and oleic acid (OA) and
polyunsaturated fatty acids stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) for 24 h
(n= 4–12 biologically independent experiments) For all: ***P < 0.001 and **P<0.01 (g, h). Quantification of IL-6 and CXCL1 expression from siGpx4 and
siCtrl IECs stimulated with PA, POA, OA, SDA, EPA, DPA, and DHA for 24 h by ELISA (n= 4–11 biologically independent experiments). ***P < 0.001 and
**P < 0.01. i, j Quantification of IL-6 and CXCL1 production from siGpx4 and siCtrl IECs stimulated with TNFα or IL-1β for 24 h by ELISA (n= 4 biologically
independent experiments). For panel (a), (c) and (e–j) data are presented as boxblot with median and interquartile range (25th and 75th). The whiskers
represent minimal and maximal values. For panel (b) and (d) data presented as mean ± SEM. For panel (a–j) to (j) one-way ANOVA with Bonferroni
multiple comparison test or a Kruskal–Wallis test with Dunn’s multiple comparison test was used with the exception of panel (b) and (d) for which a two-
way ANOVA with Bonferroni post-hoc test was used and panel (f) and (g) for which an unpaired two-tailed Student’s t test was used. Source data are
provided as a Source Data file.
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mice was characterized by signs of epithelial LPO (Fig. 3e),
expression of Cxcl1 (Fig. 3f) and infiltration of MPO+ and GR1+
neutrophils (Fig. 3g, h). Gpx4+/−IECmice also exhibited higher levels
of circulating leukocytes and specifically neutrophil granulocytes in
the blood (Fig. 3i). We observed a similar enteritis severity in male
and female Gpx4+/−IEC mice (Supplementary Fig. 4C). Notably, a
Western diet (rich in saturated fatty acids) did not induce intestinal
inflammation in Gpx4+/−IEC mice (Fig. 3b, d and Supplementary
Fig. 4D). Although PUFA stimulation (but not cytokines, bile acids
or lipopolysaccharide) impaired epithelial GPX4 activity likely
because of proteasomal degradation of GPX4 (Supplementary
Fig. 5A-H) and Gpx4 deficiency induced ferroptosis of MODE-K
IECs to some extent (Supplementary Fig. 6A-I), we did not observe
IEC death in Gpx4+/−IEC mice on a PUFA-enriched Western diet
(Supplementary Fig. 6J-L). These data indicated that cell death was
not a prerequisite of PUFA-induced and GPX4-restricted intestinal
inflammation in Gpx4+/−IEC mice.
Cytokine production is driven by ferroptosis mechanisms. We
focused on regulatory mechanisms that control AA-induced
cytokine production because AA entails a risk for developing
IBD20,21. As we noted that AA stimulation promoted LPO only in
Gpx4-deficient IECs (Fig. 2a) and cellular iron availability and
lipoxygenases (LOX) control LPO in Gpx4-deficient cells1,30, we
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analyzed the impact of iron and LPO on GPX4-restricted cyto-
kine production. Ferric iron promoted LPO (Fig. 4a) and AA-
induced cytokine production in siGpx4 IECs (Fig. 4b, c), despite a
reduced iron uptake that could not be explained by differential
regulation of iron transporters (Supplementary Fig. 7A–G). Vice
versa, iron chelation with deferoxamine (DFO) reduced IL-6 and
CXCL1 responses of siGpx4 IECs upon AA stimulation (Fig. 4d, e).
Moreover, AA-induced cytokine responses were ameliorated by
the LPO scavenger ferrostatin-1 and α-tocopherol (Fig. 4f–h).
Similarly, inhibition of LOX15 ameliorated AA-induced LPO
(Supplementary Fig. 7H) and cytokine production of siGpx4 IECs
(Fig. 4i, j). Co-silencing of Alox15 (or Alox12) also ameliorated
the cytokine response of siGpx4 IECs after AA stimulation
(Fig. 4k and Supplementary Fig. 7I, J). The non-selective COX1/2
inhibitor piroxicam abolished neither CXCL1 production nor LPO
(Supplementary Fig. 7K, L). Collectively, these data demonstrate
that iron availability promoted PUFA-induced LPO and cytokine
production in IECs with reduced GPX4 activity, which was reversed
by α-tocopherol.
AA and ferric maltol induce enteritis in Gpx4+/−IEC mice.
These findings led us to study the direct impact of AA and ferric
iron on intestinal inflammation. Indeed, intestinal epithelial orga-
noids from Gpx4+/−IEC mice, but not WT controls, displayed signs
of LPO and increased Cxcl1 expression on AA and ferric iron
exposure (Fig. 5a, b and Supplementary Fig. 8a), while unstimu-
lated Gpx4+/−IEC organoids were indistinguishable from WT
organoids (Supplementary Fig. 8B-G). Next, we orally challenged
8-week old WT and Gpx4+/−IEC mice with AA once daily for five
consecutive days complementary to the standard chow diet in
addition to iron supplementation with ferric maltol (Fig. 5c), which
is approved for treatment of iron-deficiency anemia in IBD31. We
used this model as it may reflect a daily PUFA and iron challenge
in humans on a meat-enriched Western diet19. WT mice were
unaffected by oral AA and ferric maltol exposure (Fig. 5d, e). In
contrast, Gpx4+/−IEC mice exhibited inflammation in the intestine
when exposed to AA and ferric maltol (Fig. 5d, e). More specifi-
cally, acute inflammation in Gpx4+/−IEC mice was characterized by
neutrophil infiltration in the proximal small intestine (Fig. 5d, e),
the locale of PUFA and iron absorption32,33, as corroborated by
flow cytometry of GR1+ neutrophils (Fig. 5f) and immuno-labeling
of MPO+ cells (Supplementary Fig. 8H). Neutrophilic infiltration
was paralleled by signs of epithelial LPO (Fig. 5g) and increased
Cxcl1 expression (Fig. 5h). Notably, ferric maltol or AA exposure
alone did not evoke neutrophilic inflammation in Gpx4+/−IEC
mice (Fig. 5e). The abundance of other mucosal innate and
adaptive immune cells remained comparable between WT and
Gpx4+/−IEC mice exposed to AA and ferric maltol (Supplementary
Fig. 9A–H) and we did not note colonic inflammation (Supple-
mentary Fig. 10A). These data demonstrated that intestinal epi-
thelial GPX4 restrained neutrophilic small intestinal inflammation
induced by AA and ferric maltol. In line with a critical role of
LPO in inflammation, α-tocopherol treatment protected against
PUFA-induced LPO and cytokine production (Fig. 4f–h) and
neutrophilic infiltration in Gpx4+/−IEC mice challenged with AA
and ferric maltol (Fig. 5i). Similarly, α-tocopherol, as well as
liproxstatin-1 treatment, protected against enteritis in Gpx4+/−IEC
mice induced by a PUFA WD (Fig. 5j, k), which was associated
with reduced signs of LPO and neutrophil infiltration (Supple-
mentary Fig. 10B–D).
Cytokine production is governed by ACSL4. To further explore
how AA may instigate cytokine production, we used liquid
chromatography tandem mass spectrometry (LC-MS/MS) to
investigate the AA metabolite profile of siGpx4 IECs as compared
to that of controls. AA may be metabolized by cyclooxygenases
(COX), lipoxygenases (LOX) and cytochrome P450 enzymes to
bioactive lipid mediators, which occurred to a similar extent in
AA-stimulated siGpx4 and siCtrl IECs (Fig. 6a–c, Supplementary
Table 3). In line with this, Lox and Cox expression was com-
parable between siCtrl and siGpx4 IECs (Supplementary
Fig. 11A). As Acsl4 is required for IEC ferroptosis (Supplemen-
tary Fig. 6I)2,6, we next hypothesized that AA-induced inflam-
mation in siGpx4 IECs required ACSL4. Indeed, Acsl4 deletion
abolished AA-induced IL-6 and CXCL1 production in siGpx4
IECs (Fig. 6d, e).
Next, we sought to understand how ACSL4 controlled AA-
induced cytokine responses. Notably, Acsl4 deletion in siGpx4
IECs did not protect against LPO after AA exposure (Supple-
mentary Fig. 11B). These data indicated that ACSL4 controlled
AA-induced cytokine production using a distinct mechanism that
was independent of LPO. To explore a role of ACSL4 in AA
metabolism, we analyzed the metabolite profile in Acsl4−/− IECs
by means of LC-MS/MS (Fig. 6a-c). Indeed, Acsl4−/− IECs
exhibited a decreased abundance of LOX and COX metabolites
after AA stimulation in siCtrl and siGpx4 IECs (Fig. 6a, b).
Fig. 3 PUFA enrichment of a Western diet induces focal enteritis in Gpx4+/−IEC mice. a Representative small intestinal H&E images of Gpx4+/−IEC mice
and WT littermates on a chow diet (n= 10 mice per group). Scale bars indicate 100 µm. b Representative H&E images of WT and Gpx4+/−IEC mice
exposed to a low-fat diet (LFD), a Western diet (WD) or a PUFA-enriched WD (PUFA WD) for 3 months. Note that the PUFA WD evoked focal enteritis
characterized by mono- and polymorphonuclear cell infiltration, crypt hyperplasia, and mucosal injury in Gpx4+/−IEC mice (n= 8 mice for WT LFD, n= 9
mice for Gpx4+/−IEC LFD, n= 7 mice for WT WD, n= 10 mice for Gpx4+/−IEC WD, n= 9 mice for WT PUFA WD and n= 11 mice for Gpx4+/−IEC PUFA
WD). Scale bars indicate 100 µm. c Granuloma-like accumulation of inflammatory cells and submucosal infiltration of inflammatory cells in Gpx4+/−IEC
mice exposed to a PUFA-enriched WD for 3 months (red arrows) (n= 11). Scale bars indicate 100 µm. d Histology score of WT and Gpx4+/−IEC mice
exposed to a low-fat diet (LFD), a Western diet (WD) or a PUFA-enriched WD (PUFAWD) for 3 months. Each dot indicates one experimental animal (n=
8 mice for WT LFD, n= 9 mice for Gpx4+/−IEC LFD, n= 7 mice for WT WD, n= 10 mice for Gpx4+/−IEC WD, n= 9 mice for WT PUFA WD and n= 11
mice for Gpx4+/−IEC PUFA WD). Median shown, ***P < 0.001. One-way ANOVA with Bonferroni’s multiple comparison test. e Representative 4-HNE
immunoreactivity (brown), indicative for LPO (n= 5 mice per group). Scale bars indicate 100 µm. f Relative Cxcl1 expression determined by qPCR (n= 4
mice for WT LFD, n= 6 mice for Gpx4+/−IEC LFD, n=4 mice for WTWD, n= 6 mice for Gpx4+/−IEC WD, n=8 mice for WT PUFAWD, and n= 11 mice for
Gpx4+/−IEC PUFA WD). *P= 0.0288. One-way ANOVA with Bonferroni correction. g Representative images of MPO+ cells in Gpx4+/−IEC and WT mice
on a PUFA-enriched WD (n= 5 mice per group). The red arrows denote granuloma-like lesions with MPO+ cells (brown) intermingled between crypts
marked with asterisks. Scale bars indicate 50 µm and 100 µm, respectively. h Representative confocal images of GR-1+ neutrophils (red) in Gpx4+/−IEC and
WT mice on a PUFA-enriched WD (n= 4 mice per group). DAPI stained nuclei blue. Dashed line denotes basal membrane; L, luminal-oriented side.
Asterisks denote crypt units. Scale bars indicate 50 µm. i Leukocyte count and neutrophil granulocyte count from whole blood samples of Gpx4+/−IEC and
WT mice after a 3-month PUFA-enriched WD (Left panel n= 11 mice, right panel n= 11 mice for WT and n= 12 mice for Gpx4+/−IEC). *P= 0.0361, ***P <
0.001. Unpaired two-tailed Student’s t test. Source data are provided as a Source Data file.
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However, none of the abundant LOX and COX lipid mediators
(i.e. 5-HETE, a 15-HETE precursor or PGE2) was able to promote
the production of IL-6 or CXCL1 in our model (Supplementary
Fig. 11C–H). These data suggested that modulation of LOX and
COX metabolism by ACSL4 did not affect the inflammatory tone.
However, we noted that P450 metabolites of AA (i.e. epoxyeico-
satrienoic acids or ‘EETs’) were increasingly accumulating in
Acsl4−/− IECs after AA stimulation (Fig. 6c). A combination of
EETs ameliorated AA-induced IL-6 and CXCL1 production in
siGpx4 IECs (Fig. 6f, g), likely due to their anti-inflammatory effect
that suppressed NF-κB34. In line with this, we noted that AA
induced activation of NF-κB p65 in siGpx4 IECs (Supplementary
Fig. 11I, J), and NF-κB inhibition with BAY11-7082 or MG132
abolished IL-6 production in siGpx4 IECs independent of LPO
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(Supplementary Fig. 11K, L). As such, Acsl4 deletion may limit
AA-induced cytokine responses by modulating AA metabolism34,
while GPX4 controlled LPO.
Discussion
Westernization of dietary habits, partially characterized by
enrichment with PUFAs35,36, paralleled the increased IBD inci-
dence19. Previous observations associated PUFA uptake and
mucosal AA accumulation with the risk of developing IBD20,21,37.
Large prospective clinical trials in CD patients (and patients
without IBD) indicated that PUFA supplementation may cause
gastrointestinal side effects (e.g. diarrhea), indicative for disturbed
intestinal homeostasis38,39. In contrast, dietary restriction (e.g.
by an elemental diet) ameliorates the course of CD40,41. These
reports and other studies15 indicate that dietary cues impact
the risk of developing CD and affect the natural history of disease.
However, a direct link between PUFA uptake and intestinal
inflammation remained elusive. Our study establishes that
dietary-derived PUFAs trigger neutrophilic inflammation in the
small intestine resembling some aspects of human CD.
IECs have the delicate task of maintaining a physical and
immunological line of defense to protect the host against a
potentially hostile environment. At the same time IECs must
continue to allow uptake of essential nutrients such as long-chain
fatty acids42. A hypoxic milieu and exposure to luminal noxae
may specifically require GPX4 activity in IECs to protect against
cellular LPO, a critical condition that determines cell fate1. While
substantial advances have shaped our understanding of ferrop-
tosis1, GPX4-restricted immunologic responses remain poorly
explored despite reports of inflammatory tissue injury in GPX4-
deficient animals9,11,27. We report that IECs with reduced GPX4
activity respond to non-toxic dietary PUFA exposure with an
inflammatory response involving IL-6 and CXCL1. PUFA-
induced CXCL1 production of siGpx4 IECs was comparable to
CXCL1 production induced by TNFα stimulation. In contrast IL-
6 production was far less pronounced in PUFA-stimulated siGpx4
IECs, when compared to TNFα stimulation. Future studies will
delineate the relevance of both cytokines as driver of mucosal
inflammation in our model. Notably, exposing ω-3 PUFAs such
as DHA (which is thought to exert anti-inflammatory effects43)
elicited cytokine production similar to AA (which is thought to
exert inflammatory effects) only in Gpx4-deficient IECs. As such
it appears that the availability (rather than the positioning) of
double bonds within PUFAs define their propensity to fuel LPO
and an inflammatory response. These findings led us to explore
the consequences of PUFA exposure on IECs with impaired
GPX4 activity in the intestine. We generated mice with IEC-
specific deletion of one Gpx4 allele (Gpx4+/−IEC), which is a
valuable tool for modeling the effects of reduced, but not com-
pletely abrogated epithelial GPX4 activity as observed in patients
with small intestinal CD. Indeed, a PUFA-enriched WD con-
taining 10% fish oil (with ω-3 and ω-6 PUFAs) evoked focal
neutrophilic enteritis in male and female Gpx4+/−IEC mice that
was characterized by granuloma-like mucosal to submucosal
accumulation of inflammatory cells and expression of the IL-8
homologue Cxcl1. As such, our findings represent first evidence
that non-toxic dietary lipids trigger focal enteritis in a genetically
susceptible host resembling some aspects of human small
intestinal CD. Future studies are warranted to explore the
immune-phenotype in more detail. Notably, a WD rich in satu-
rated fatty acids (without addition of fish oil) did not induce
intestinal inflammation in Gpx4+/−IEC mice, indicating that
PUFA supplementation specifically elicited the inflammatory
phenotype.
We did not note colonic intestinal inflammation in PUFA
WD- or AA/FM-exposed Gpx4+/−IEC mice, suggesting that
environmental cues may determine disease localization. We
speculate that PUFAs and iron are specifically absorbed in the
small intestine32,33,44, which could be one explanation for small
intestinal disease localization and a requirement for GPX4 activity
in the small intestine. In line with a small intestinal phenotype in
mice, we specifically noted reduced epithelial GPX4 activity in
active small intestinal CD. In contrast, we did not note altered
GPX4 activity in colonic CD or UC.
Of note, fish oil supplementation has been tested in the
maintenance of remission in CD patients with mixed results. More
specifically, fish oil supplementation had favorable effects on
maintenance of remission in some patients45, while larger studies
observed no beneficial effect but worsening of gastrointestinal
symptoms (e.g. diarrhea)45–47. This observation indicates that
dietary PUFA exposure impacts the course of CD. Similarly,
PUFA supplementation induces gastrointestinal symptoms (diar-
rhea, abdominal pain and nausea) in patients without IBD39.
Which factors define a beneficial or detrimental response on
PUFA challenge (e.g. fish oil or other sources such as fish, meat
and eggs) in CD (or healthy) patients is unknown. Our data
indicate that PUFAs trigger GPX4-restricted mucosal inflamma-
tion resembling some aspects of human CD.
Ferroptosis is fundamentally controlled by lipoxygenase-
driven LPO, which is limited by GPX4 and driven by cellular
iron availability1. Similarly, we found that PUFA exposure
induced LPO and cytokine production of siGpx4 IECs, while
pharmacologic iron chelation with DFO, inhibition of lipox-
ygenases and LPO scavenging with α-tocopherol ameliorated this
phenotype. Genetic deletion of Acsl4 (which is required for
ferroptosis2,6), abrogated PUFA-induced cytokine production in
IECs with reduced GPX4 activity. While GPX4 did not control
AA metabolism, we found that ACSL4 limited the generation of
anti-inflammatory AA metabolites (epoxyeicosatrienoic acids or
‘EETs’), which have been demonstrated to inhibit NF-κB
Fig. 4 Iron availability, lipoxygenases and LPO control PUFA-induced cytokine production. a LPO quantification after 24 h stimulation with AA and ferric
iron (5 µM Fe(III) sulfate) or vehicle (n= 6 biologically independent experiments). *P= 0.0234. b, c Quantification of IL-6 and CXCL1 in the supernatant
from siGpx4 and siCtrl IECs stimulated with AA and ferric iron or vehicle for 24 h (n= 4 biologically independent experiments).*P= 0.0479 for (b) and
*P=0.0259 for (c). d, e Quantification of IL-6 and CXCL1 in the supernatant from siGpx4 and siCtrl IECs stimulated with AA and deferoxamine (DFO) or
vehicle (n= 6 biologically independent experiments). ***P < 0.001 for (d) and (e). f LPO quantification by flow cytometry of BODIPY581/591 C11+-labeled
IECs after 24 h stimulation with AA and α-tocopherol (α-toco) or vehicle (n= 6 biologically independent experiments). *P= 0.0199. g, h Quantification of
indicated cytokines in the supernatant from siGpx4 and siCtrl IECs after 24 h AA stimulation co-treated with LPO scavengers (n= 6 biologically
independent experiments in (g) and n= 4 biologically independent experiments in (h)). ***P < 0.001. i, j Cytokine quantification in the supernatant of
siGpx4 and siCtrl IECs after 24 h AA stimulation and treatment with selective LOX inhibitors (n= 5 for vehicle and n= 3 for indicated inhibitors; biologically
independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001. k Quantification of CXCL1 in the supernatant from siGpx4 and siAlox12 or siAlox15 co-silenced
IECs stimulated with AA (20 µM) for 24 h (n= 4 biologically independent experiments). ***P < 0.001. Data are presented as boxblot with median and
interquartile range (25th and 75th). The whiskers represent minimal and maximal values. One-way ANOVA with Bonferroni’s multiple comparison test or
Kruskal–Wallis Test with Dunn’s multiple comparison test was used. Source data are provided as a Source Data file.
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activity34. Indeed, a combination of EETs, but not a single EET
alone, reduced AA-induced cytokine production similar to
pharmacologic inhibition of NF-κB. These data suggest that
GPX4-restricted LPO and ACSL4-controlled AA metabolism
converge on NF-κB-mediated transcription of inflammatory
cytokines specifically in GPX4-deficient IECs. As such, the same
mecha-
nisms (i.e. iron availability, LOX-mediated LPO and ACSL4) that
control ferroptosis1 also control PUFA-induced cytokine pro-
duction in siGpx4 IECs. These findings lay the foundation for
understanding dietary lipid-induced intestinal inflammation.
Indeed, AA and ferric maltol (approved for the treatment of
iron-deficiency anemia in IBD31) triggered epithelial LPO, Cxcl1
expression and small intestinal neutrophilic infiltration in
Gpx4+/−IEC mice. Similarly, Gpx4+/−IEC mice exposed to a
PUFA WD exhibited increased LPO and neutrophilic inflam-
mation, and LPO scavenging with α-tocopherol ameliorated
enteritis in both models. These findings indicate that GPX4
protects against epithelial LPO, which sets a threshold for
intestinal inflammation triggered by dietary lipids. Although
LPO is a key feature of ferroptosis1, cell death was not a pre-
requisite for intestinal inflammation indicated by a lack of epi-
thelial TUNEL labeling in Gpx4+/−IEC mice. One reason for this
may be that one Gpx4 allele is sufficient to protect against fer-
roptotic IEC death, but insufficient to prevent PUFA-induced
cytokine production. In this context, studies in heterozygous
Gpx4 knockout mice did not report cell death (or related organ
dysfunction)11,29,48. Future work may define a role for ferrop-
totic cell death in mucosal inflammation.
Collectively, our data support a model in which dietary PUFAs
elicit neutrophilic inflammation, which emanates from IECs with
reduced GPX4 activity (Supplementary Fig. 12). Our findings
turn the spotlight onto GPX4-restricted oxidative processes,
which determine the competence of the epithelium to cope with
environmental cues that inevitably occur on mucosal surfaces.
Impaired GPX4 activity observed in small intestinal CD may arise
from dietary long-chain fatty acids (Supplementary Fig. 5), (yet
unidentified) immune mediators, bile salts49 or microbial
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metabolites50 that are absorbed in the small intestine. As we
specifically observed impaired GPX4 activity in IECs from the
inflamed (but not uninflamed) mucosa of CD patients, it appears
plausible that GPX4 deficiency is no primary defect in CD but
occurs secondary to insults (likely caused by yet unidentified
cellular stressors) in the inflamed mucosa. We speculate that IBD-
related genetic cues may impinge on GPX4 activity during
inflammation51, and that genetic and environmental mucosal
insults (other than PUFAs) trigger an inflammatory response in
GPX4-deficient hosts52. Future studies will advocate a critical role
of oxidative processes on cellular membranes of IECs and deci-
pher the impact of oxidized lipid species in mucosal inflammation
and IBD53–55.
Methods
Human studies. IBD patients were recruited in the gastroenterology outpatient
clinic of the Medical University of Innsbruck and included when a definitive IBD
diagnosis (by clinical, endoscopic, and histopathological means) was established
and informed consent was obtained. Healthy controls undergoing screening
colonoscopy—which lacked endoscopic and histological signs of intestinal disease
—were included after informed consent was obtained. Patients were excluded if
any of these criteria were not fulfilled or if the histology report and the endoscopic
report conflicted. Ileal and colonic biopsies were collected from IBD patients and
healthy controls, stored on ice in RPMI medium or formalin and processed the
same day. One biopsy was used for mRNA isolation and one biopsy was formalin-
fixed and paraffin-embedded for histology. Remaining biopsies were used to isolate
IECs according to the section IEC isolation. IEC suspensions were snap-frozen in
lysis buffer and stored at −80 °C until GPX4 enzymatic activity testing (see section
GPX4 enzymatic activity assay) or protein analysis by western blot (see section
Immunoblot).
Mice. C57BL/6J Gpx4flox/flox mice27 were crossed with C57BL/6J Villin-Cre+ mice28
to obtain Gpx4flox/wt;Villin-Cre+/− (Gpx4+/−IEC) mice or Gpx4flox/flox;Villin-Cre+/−
(Gpx4−/−IEC) mice. All experiments were performed with male and female 7- to 10-
week-old mice. Littermates of the same sex were randomly assigned to experimental
groups and were fed a chow diet or a Western diet (ssniff, TD88137) with or
without 10% fish oil (ssniff supplementation, see Table S2). Gpx4−/−IEC breeding
pairs were fed an α-tocopherol enriched diet (sniff, E157892-14, +500mg/kg
Tocopheryl Acetate) until weaning in the animal facility in Erlangen. In all other
experiments Gpx4+/−IEC mice and WT controls were co-housed under SPF con-
ditions (ZVTA) at the Medical University of Innsbruck.
Mouse treatment. 7- to 10-week-old WT and Gpx4+/−IEC mice received daily ferric
maltol (0.4 mg, Shield Therapeutics PLC) and/or arachidonic acid (10mg, Sigma,
10931) via oral gavage over the course of 6 days with or without α-tocopherol
supplementation (0.4mg/ml, Sigma) in drinking water ad libitum. During the
experiment, mice were fed a chow diet ad libitum. On day 6 mice were sacrificed for
tissue collection.
Dextran sodium sulfate (DSS) colitis was induced in 8-week-old co-housed WT
and Gpx4+/−IEC mice using 3% DSS (MP Biomedicals, 02160110) given in
drinking water ad libitum for five consecutive days followed by tap water for the
rest of the experiment. Disease activity was assessed as previously described56.
To investigate the influence of a Western diet, 7- to 10-week-old WT and
Gpx4+/−IEC mice were fed a Western diet (ssniff, TD88137) with or without 10%
fish oil (ssniff supplementation, see Table S2) and compared to mice receiving a
low-fat diet (ssniff, CD88137) for 3 months ad libitum with or without α-
tocopherol supplementation (0.4 mg/ml, Sigma) in drinking water ad libitum.
Bodyweight was assessed weekly. After 3 months mice were sacrificed for tissue
collection.
To test the anti-inflammatory effect of Liproxstatin-1 7- to 10-week-old WT
and Gpx4+/−IEC mice were fed a Western diet (ssniff, TD88137) with 10% fish oil
(ssniff supplementation, see Table S2) for 3 months ad libitum. After 6 weeks of
feeding, mice received 10 mg/kg Liproxstatin-1 (Cayman Chemicals, 17730) or
vehicle (5% DMSO in PBS) every other day by i.p. injection until closure of the
experiment.
Blood count. Heparin blood samples were used to perform complete blood count
analysis on a Vet-ABC animal blood counter (scil animal care company GmbH,
Viernheim, Germany).
Cell culture. MODE-K cells (Mus musculus, small IECs, kindly provided by D.
Kaiserlian) were cultured in high-glucose DMEM (Lonza, BE12-604F), 10% FCS
(Biochrome, S0115), HEPES (10 mM, Biochrome, L1613), non-essential amino
acids (1 mM, Gibco, 11140-035), 100U/ml penicillin and 100 µg/ml streptomycin
(1% Biochrome, 0257 F). HEK293T cells (Homo sapiens, female, embryonic kidney
cells, ATCC, CRL-1573) were cultured in high-glucose DMEM (Lonza, BE12-
604F), 10% FCS (Biochrome, S0115), HEPES (10 mM, Biochrome, L1613), non-
essential amino acids (1 mM, Gibco, 11140-035), 100U/ml penicillin and 100 µg/ml
streptomycin (1% Biochrome, 0257 F) and 2 mM sodium pyruvate (1% Biochrome,
L 0473). Cells were cultured at 37 °C in 5% CO2.
Reagents. The following reagents were used for cell stimulation: deferoxamine (0.1-
20 µM, Sigma, D9533), ß-thujaplicin (Hinokitol, Sigma, 469521), deferasirox
(Exjade®, Novartis), fe(III) sulfate hydrate (2-20 µM, Sigma, F0638), arachidonic acid
(AA, 20 µM, Sigma, A3611), docosahexaenoic acid (DHA, 500 µM, Sigma, D2534),
palmitic acid (PA, 250 µM, Sigma, P5585), oleic acid (OA, 250 µM, Sigma, O1008),
palmitoleic acid (POA, 100 µM, Sigma P9417), stearidonic acid (SDA, 50 µM, Sigma
SMB00291), eicosapentaenoic acid (EPA, 100 µM. Sigma E2011), docosapentaenoic
acid (DPA, 25 µM, Sigma D1797) ferrostatin-1 (fer-1, 0.01–1 µM, Sigma, SML0583),
α-tocopherol (α-toco, 0.1–1 µM, Sigma, T3251), Z-VAD-FMK (0.1–100 µM, BD
Bioscience, 550337), TNFα (50 ng/ml, PeproTech), IFNγ (50 ng/ml, R&D), IL-1β
(10 ng/ml, PeproTech), LPS (100 ng/ml, Sigma L4524), IFNβ (2500U/ml, PBL,
12401-1), IL-4 (10 ng/ml, PeproTech 214-14), IL-6 (20 ng/ml, PeproTech 216-16),
Fig. 5 AA and ferric maltol induce neutrophilic inflammation in Gpx4+/−IEC mice. a Representative confocal microscopy images of 4-HNE-labeled
organoids (green) from indicated genotypes after stimulation with AA and ferric iron or vehicle for 24 h. Scale bars indicate 20 µm (n= 3 biologically
independent samples). b Cxcl1 expression after 48 h AA and ferric iron stimulation of indicated organoids determined by qPCR (n=11 biologically independent
samples). Data are presented as boxblot with median and interquartile range (25th and 75th). The whiskers represent minimal and maximal values. *P=
0.0303. c Model of arachidonic acid and ferric maltol gavage. d, e Representative H&E images (d) and histology score (e) of indicated genotypes orally
exposed to ferric maltol and/or AA as indicated in (c). The red arrows denote neutrophils. Scale bars indicate 100 µm and 50 µm, respectively. Each dot
represents one experimental animal (n= 8 mice for WT AA, n= 7 mice for Gpx4+/−IEC AA, n= 7 mice for WT FM, n= 7 mice for Gpx4+/−IEC FM and n= 18
mice for WT AA+FM and n= 25 mice for Gpx4+/−IEC AA+FM). ***P < 0.001. f Neutrophilic infiltration of GR1+ neutrophils by flow cytometry of indicated
genotypes from the experiment shown in (c). Each dot represents one experimental animal (n= 6 WT mice and n= 5 Gpx4+/−IEC mice). *P=0.0228.
g Representative images of 4-HNE immunoreactivity (brown), indicative for LPO (n= 5 mice per group). Scale bars indicate 100 µm. h Quantification of Cxcl1
expression determined by qPCR in intestinal epithelial scrapings of indicated genotypes from the experiment shown in (c). Each dot represents one
experimental animal (n= 10 mice per group). P= 0.0435. Mann–Whitney test. i Histology score of AA- and ferric maltol-exposed mice with or without α-
tocopherol supplementation [0.4mg/ml] in drinking water over the course of the experiment. Each dot represents one experimental animal (n= 4 mice for
WT + vehicle, n= 7 mice for WT + α-toco, n= 9 mice for Gpx4+/−IEC + vehicle and n= 8 mice for Gpx4+/−IEC + α-toco). P=0.0302. j Enteritis histology
score of WT and Gpx4+/−IEC mice exposed to a PUFA-enriched WD (PUFA WD) for 3 months with and without α-tocopherol supplementation [0.4mg/ml]
in drinking water over the course of the experiment. Each dot represents one experimental animal. Median shown (n= 9 mice for WT PUFA WD + vehicle,
n= 14 mice for Gpx4+/−IEC PUFAWD+ vehicle, n= 9 mice PUFAWD+ α-toco). **P < 0.01. k Enteritis histology score of WT and Gpx4+/−IECmice exposed
to a PUFA-enriched WD (PUFA WD) for 3 months with and without liproxstatin-1 treatment intraperitoneally from 6 weeks [10mg/kg] until the closure
of the experiment. Each dot represents one experimental animal. Median shown (n= 5 mice for WT PUFA WD + vehicle, n= 8 mice for Gpx4+/−IEC PUFA
WD+ vehicle, n= 9 mice PUFAWD+ liproxstatin-1). ***P < 0.001. For panel (e), (f), (h), and (i) data are presented as mean±SEM. For panel (b), (f) and (h)
unpaired two-tailed Student’s t test and for panel (e) and (i–k) one-way ANOVA with Bonferroni’s multiple comparison test was used. Source data are
provided as a Source Data file.
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IL-22 (10 ng/ml, PeproTech 210-22), cholic acid (1 µM, Sigma C9282), deoxycholic
acid (1 µM, Sigma D2510), ursodeoxycholic acid (1 µM, Sigma U5127),(+/−)8(9)-
and (+/−)11(12)- and (+/−)14(15)-EETs (0.25 µM Cayman Chemicals, 50511,
50651, 50351), ML351 (10 µM, Sigma, SML1353), PD146176 (0.5 µM, Sigma,
P4620), zileuton (10 µM, Sigma, Z4277), NCTT-956 (2 µM, Sigma, SML0499), pir-
oxicam (20 µM, Sigma, P5654), 5-HETE (200nM-1µM, Cayman Chemicals, 34210),
15-HPETE (200nM-1µM, Cayman Chemicals, 44720), PGE2 (50 ng/ml, Sigma,
P0409), BAY117082 (10 µM, Sigma, B5556), MG132 (125 nM, ApexBio, A2585).
siRNA silencing. MODE-K IECs were seeded on 6-well plates at ~70% confluence
for siRNA silencing with either Gpx4 siRNA (siGpx4, Ambion, s122098), Alox12
(siAlox12, Ambion, s62261), Alox15 (siAlox15, Ambion, s62271) or scrambled
control siRNA (siCtrl, Ambion 4390843) and RNAiMAX (Thermo Fisher Scien-
tific, 13778100) transfection over 48 h unless otherwise indicated, according to the
recommended protocol.
CRISPR Cas9 gene editing. Target genes were disrupted in MODE-K IECs using
the CRISPR/Cas9 system26. For each gene three guide RNAs (gRNA) targeting
different exons of the target gene were designed. gRNAs with specific overhangs
were annealed into a BsmBI-digested plentiCRISPRv2 plasmid (Addgene #52961,
gift from Feng Zhang)57. Vectors were transfected into HEK293T cells (ATCC®
CRL-1573™) to produce viral particles. Harvested supernatants were used for gene
knockout. For transfection, MODE-K cells were seeded on 6-well plates and
infected with viral particles containing the constructed vectors. The guide RNA
sequence used for studies in Gpx4-/- IECs was CGTGTGCATCGTCACCAACG,
which targeted exon 1. The guide RNA sequence used for studies in Acsl4-/- IECs
was CAATAGAGCAGAGTACCCTG, which targeted exon 6. To generate Gpx4-/-
and Acsl4-/- clones by CRISPR Cas9 gene editing, transfection was performed for
48 h followed by puromycin (Gibco, A1113803) selection for 10 days and sub-
sequent seeding onto 96-well plates with one cell per well for expansion.
Human intestinal epithelial organoids. Human organoids were cultured from
IEC isolates of biopsy specimens retrieved from endoscopy of CD patients and
healthy controls using IntestiCult Organoid Growth Medium (Stemcell Technol-
ogies) and a protocol adapted from the manufacturer’s instructions. Briefly,
biopsies were flushed with 10 ml of ice cold PBS and minced into the small pieces.
Tissue was then transferred to 5 ml Gentle Cell Dissociation Reagent (Stemcell
Technologies) and incubated at 4 °C on a rocking platform for 30 min. After
centrifugation at 4 °C and 290g for 5 min supernatant was removed and crypts were
transferred to 1 ml of ice cold 1% BSA/DMEM. Crypts were dissolved by gentle
mixing and passed through a 70 µm cell strainer. Seeding was identical to that for
mouse organoids (see below). Human organoids were passaged with a split ratio of
1:3 every 7–14 days.
Mouse intestinal epithelial organoids. Intestinal epithelial organoids were cul-
tured from 4- to 8-week-old Gpx4+/−IEC and littermate WT mice using IntestiCult
Organoid Growth Medium (Stemcell Technologies, 06005) and a protocol adapted
from manufacturer’s instructions as initially described58. Briefly, small intestines
were flushed with ice cold PBS, minced to pieces of approximately 2–3 mm in size
and washed up to five times with 10 ml ice cold PBS. Samples were transferred to
a
M
et
ab
ol
ite
 in
 p
g/
m
illi
on
 IE
Cs
0
5000
10000
15000
20000
LXB4
LXA4
LTB4
15-HETE
12-HETE
5-HETE
siC
trl
siG
px4
 
siC
trl;
Ac
sl4
−
/−
siG
px4
;Ac
sl4
−
/−
siC
trl
siG
px4
 
siC
trl;
Ac
sl4
−
/−
siG
px4
;Ac
sl4
−
/−
siC
trl
siG
px4
 
siC
trl;
Ac
sl4
−
/−
siG
px4
;Ac
sl4
−
/−
siC
trl
siG
px4
 
siC
trl;
Ac
sl4
−
/−
siG
px4
;Ac
sl4
−
/−
siC
trl
siG
px4
 
siC
trl;
Ac
sl4
−
/−
siG
px4
;Ac
sl4
−
/−
siC
trl
siG
px4
 
siC
trl;
Ac
sl4
−
/−
siG
px4
;Ac
sl4
−
/−
Vehicle AA Vehicle AA Vehicle AA
0
10000
20000
30000
TXB2
6-K-PGF1A
PGE2
b
0
5000
10000
15000
20000
25000
14,15-DHET
11,12-DHET
8,9-DHET
5,6-DHET
14,15-EET
11,12-EET
8,9-EET
5,6-EET
c
d
IL
-6
 [p
g/m
l]
***
Ac
sl4
–
/–
Ctr
l
Ac
sl4
–
/–
Ctr
l
AA
0
500
1000
1500
2000
2500
3000
CX
CL
1 
[pg
/m
l]
***
e
0
2000
4000
6000
8000
10000
12000
AA
f
IL
-6
 [p
g/m
l]
**
Ve
hi
cl
e
EE
Ts
AA
0
300
600
900
1200
g
CX
CL
1 
[pg
/m
l]
*
Ve
hi
cl
e
EE
Ts
AA
0
2000
4000
6000
8000
M
et
ab
ol
ite
 in
 p
g/
m
illi
on
 IE
Cs
M
et
ab
ol
ite
 in
 p
g/
m
illi
on
 IE
Cs
siCtrl
siGpx4
Fig. 6 ACSL4 governs AA-induced cytokine production partly by modulation of AA metabolism. a–c Quantification of LOX (a), COX (b), and P450 (c)
AA metabolites in siGpx4 and siCtrl IECs with or without deletion of Acsl4 and AA stimulation for 24 h. Three independent experiments were performed
and pooled for metabolite analysis by LC-MS/MS. d, e Quantification of IL-6 and CXCL1 in the supernatant of siGpx4 and siCtrl IECs with or without
deletion of Acsl4 and AA stimulation for 24 h (n= 4 biologically independent experiments). ***P < 0.001. f, g Quantification of IL-6 and CXCL1 in siGpx4
and siCtrl IECs after 24 h AA stimulation co-treated with a combination of EETs (0.25 µM of (+/−) 8(9)-EET, (+/−) 11(12)-EET and (+/−) 14(15)-EET)
(n= 4 biologically independent experiments). **P= 0.0011 and *P= 0.0242. For panel (d–g) data are presented as boxblot with median and interquartile
range (25th and 75th). The whiskers represent minimal and maximal values. One-way ANOVA with Bonferroni’s multiple comparison test. Source data are
provided as a Source Data file.
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2 mM EDTA/PBS and incubated at 4 °C on a rocking platform for 30 min. After
sedimentation supernatant was removed and crypts eluted in 10 ml PBS by shaking
vigorously and passing crypts through a 70 µm cell strainer to obtain Fraction 1.
This process was repeated three times to obtain Fractions 2–4. Fractions were
analyzed under a light microscope and the optimal fraction was chosen to
obtain crypts for organoid culture by centrifugation at 290g for 5 min at 4 °C.
Crypts (N= 500) per well were seeded in 50 µl Matrigel (BD, 356231) on a pre-
warmed 24-well plate and allowed to solidify for 10 min at 37 °C, after which 500 µl
IntestiCult Growth Medium supplemented with 100U/ml penicillin and 100 µg/ml
streptomycin (Biochrome, 0257F) was added. Medium was exchanged three times
per week and organoids passaged with a split ratio of 1:6 every 7–14 days (Sup-
plementary Fig. 8A-G).
Stimulation of mouse organoids. Before stimulation, organoids were allowed to
establish for 6 days. Organoids were stimulated with arachidonic acid (AA, 100 µM,
Sigma, A3611) and Fe(III) sulfate (5 µM, Sigma, F0638) or vehicle for indicated
time periods depending on the experiment setting. Medium was replaced every
24 h. For RNA extraction TRIzol reagent (Invitrogen, 15596026) was used
according to the manufacturer’s instructions.
Immunofluorescence Imaging. Organoids were cultured with 15 µl Matrigel (BD,
356231) on chamber slides (Falcon, 354108) covered with 200 µl IntestiCult
Growth Medium supplemented with 100U/ml penicillin and 100 µg/ml strepto-
mycin (Biochrome, 0257 F). Medium was exchanged three times a week and
organoids were allowed to establish for 6 days. Organoids were stimulated as
described above for 24 h, washed with PBS and fixed with 4% PFA at room tem-
perature for 20 min, washed again twice with PBS and permeabilized with PBS-
Triton X 0.5% for 20 min at room temperature. Organoids were washed with IF
buffer (PBS, Triton X 0.3%, Tween 0.05%), blocked with blocking solution (PBS-
Triton X 0.3%, Tween 0.05%, BSA 1%), followed by another wash with IF buffer
and primary antibody in blocking solution was added over night at 4 °C. Organoids
were washed three times with IF buffer and secondary antibody was added for 1 h,
washed three times with IF buffer, mounted (Invitrogen, P36962) and analyzed
with a Zeiss Axio Observer Z1 confocal microscope and Zen 2012 software.
Intestinal sections were cryopreserved in O.C.T., acetone-fixed, stained with anti-
GR-1 and analyzed with the confocal microscope stated above.
The following antibodies were used for immunofluorescence: anti-4HNE (1:200,
Abcam, ab46545), anti-GPX4 (1:400, Abcam, ab125066) and anti-GR-1 (1:100,
BioLegend, 108413) as primary antibodies and anti-rabbit IgG Alexa Fluor 488
(1:1000, Invitrogen, A-11034) and anti-rat IgG Alexa Fluor 594 (1:1000, Invitrogen,
A-11007) as secondary antibody.
Histology. Formalin-fixed paraffin-embedded sections were hematoxylin & eosin
(H&E)-stained and assessed for inflammation by an expert pathologist using a light
microscope (Zeiss, Germany). Images were captured with a Zeiss AxioCam. In AA
and FM gavage experiments, acute inflammation was quantified by determining the
number of neutrophilic spots (>3 neutrophils in one visual field on ×20 magnifi-
cation) per section. We did not note mononuclear infiltration, hyperplasia or
ulceration in our AA and FM exposure experiments. DSS colitis severity and
enteritis evaluation was performed as reported59: Briefly, a semi-quantitative
scoring system was used that was composed of five histological subscores. Histo-
logical subscores (0, absent; 1, mild; 2, moderate; 3, severe) were mononuclear cell
infiltration, crypt hyperplasia, epithelial injury/erosion, polymorphonuclear cell
infiltration and transmural inflammation. The sum of these subscores was multi-
plied by a factor that reflected the extent of inflammation along the intestine (1,
10%; 2, 10–25%; 3, 25–50%; and 4, >50%).
Immunohistochemistry, TUNEL, BrdU, and PAS labeling. Formalin-fixed par-
affin-embedded sections were deparaffinised, rehydrated, antigen-retrieved for
15 min in sodium citrate at subboiling temperatures and peroxidase-blocked. The
primary antibody was incubated over night at 4 °C and the secondary biotinylated
antibody mediated horseradish peroxidase (HRP)-driven 3,3′-diaminobenzidine
(DAB, DAKO, K3468) turnover, which resulted n brown labeling of immunor-
eactive cells. Stained sections were analyzed with a light microscope (Zeiss, Ger-
many) and captured with a Zeiss AxioCam. TUNEL labeling was performed
according to the manufacturer’s instructions (Roche, 11684817910). TUNEL-
positive cells were quantified in 50 consecutive crypts and depicted as TUNEL+
cells of total IECs. Proliferation of IECs was investigated by intraperitoneal
injection of 5-bromodeoxyuridine (BrdU, BD Pharmigen, 550891) and detected
after 24 h using a BrdU in situ detection kit (BD Pharmigen, 550803). BrdU+ cells
of total IEC along the villus-crypt axis were analyzed. PAS reaction was performed
according to a standard protocol and PAS+ cells were counted in 50 crypt/
villus axes.
The following antibodies were used for immunohistochemistry: anti-GPX4
(1:400, Abcam, ab125066), anti-4HNE (1:400, Abcam, ab46545) and anti-MPO
(1:200, Dako, IS511) were employed with a secondary biotinylated antibody
(Vector, MP-7401).
Mouse IEC isolation. Mouse IEC isolation protocol was performed as previously
described59. Briefly, PBS-flushed and longitudinally cut intestinal pieces were
vortexed in ice cold PBS for 5 min, transferred to 30 mM EDTA, and vortexed for
5 min. The supernatant was collected and the procedure was repeated for a total of
four times. Supernatants were microscopically checked for crypt IEC enrichment
and then spun down at 800g for protein extraction or flow cytometry labeling.
Human IEC isolation. The biopsies were moved from RPMI (Biochrome, FG1385)
to HBSS-CMF buffer (Gibco, 14175-053, 0.5% BSA, 2 mM EDTA and DTT).
Samples were incubated on a shaker for 20 min at room temperature. The samples
were then vortexed vigorously and supernatant (containing IECs) was collected
through a 100 µm cell strainer, which was repeated for a total of three times.
Supernatant was then spun down at 300g and the pelle t was used for GPX4 activity
assay and western blot analysis as detailed in the respective sections.
Murine LPMC isolation. Mouse LPMCs were isolated according to previously
published protocols60,61. In short, the proximal small intestine was flushed with ice
cold PBS, opened longitudinally, cut into small pieces and transferred to HBSS
(Gibco, 14175-053) containing 10% FCS, DTT (1 mM) and EDTA (2 mM) fol-
lowed by shaking for 20 min at room temperature. Samples were vortexed to
remove IELs and the tissue was washed and collected in IMDM (Gibco, 21056-023)
20% FCS. Tissue was washed and 10U/ml DNAse (10U/ml, Sigma, D8764) and
128 U/ml collagenase (128U/ml, Sigma, C1889) digested on a shaker for 60 min at
37 °C. Cells were passed through cell strainers (100 µm) and washed twice before
transferring to cytometry buffer for staining (see below).
LPO and cell death labeling. Cells derived from cell culture or from IEC isolation
procedures were incubated with BODIPY 581/591 C11 or the surface labeling
antibodies (see below) at 37 °C in the dark for ten to 30 min in flow cytometry
buffer (2% FCS, 2 mM EDTA in PBS). Cells were subsequently washed with PBS,
resuspended in FACS buffer and transferred through a 40μm cell strainer for flow
cytometry. Annexin V, PI or 7AAD were used for cell death analysis.
Flow cytometry analysis. For LPO analysis, BODIPY-positive cells among DAPI-
negative cells were analyzed as compared to a control sample using BODIPY
measurement. For cell death analysis, debris was excluded using FSC/SSC char-
acteristics; Annexin V and PI or 7AAD positivity was determined by flow
cytometry.
FACS gating strategy. The gating strategy for analyzing the mucosal cellular
infiltrate is depicted in Supplementary Fig. 9A, E. Briefly, cells were gated using
FSC/SSC characteristics. Singlets were selected by comparing FSC width and FSC
area. Neutrophils were identified as CD45+, Lin1− (Lin1=CD3, CD19, CD49b,
DAPI) and GR1+ cells. Macrophages were identified by CD45+, Lin1−, GR1−,
CD11b+, MerTK+. Monocytes were characterized by CD45+, Lin1−, GR1−,
Ly6Chi. Dendritic cells were characterized by CD45+, Lin1−, GR1−, CD11c+ and
MHCII+. T helper cells were identified by Lin2− (Lin2=CD11c, F4/80, GR1,
DAPI), CD3+, CD19−, CD4+. Cytotoxic T cells were identified by Lin2−, CD3+,
CD19-, CD8+. B cells were defined as Lin2−, CD3-, CD19+. Details of antibodies
used are found in Supplementary Table 4.
RNA extraction and qRT-PCR. RNA was isolated from 6-well plates, epithelial
scrapings or human intestinal biopsies using an RNeasy mini kit (Quiagen 74104).
RNA was transcribed into cDNA using M-MLV reverse transcriptase (Invitrogen
28025013). Quantitative real time PCR was performed with SYBR green mastermix
(Eurogentec RT-SY2X-06+WOULR) on a MX3005 Stratagene cycler (Agilent).
The primer used in this study can be found in Supplementary Table 4.
Immunoblot. Western blot analysis was performed according to standard protocols
(Bio-Rad Laboratories). Briefly, isolated cells (from culture plates or scrapings)
were lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate, and 0.1% SDS) or M-Per (Thermo Fisher Scientific,
78501) and supplemented with protease and phosphatase inhibitors (Thermo
Fisher Scientific, 78443). Protein quantity was determined by Bradford assay (Bio-
Rad Laboratories, 5000006) and equal amounts of protein were denatured at 95 °C
in Laemmli buffer, resolved on SDS-PAGE and transferred to a polyvinylidene
fluoride membrane (Sigma, GE10600023). After blocking the membrane in 5%
skim milk, primary antibody was incubated over night at 4 °C. Signal was visualized
with HRP-conjugated secondary antibodies (Cell Signalling Technology, 7074) and
ECL Select Western Blotting Detection Reagent (Amersham, RPN2235). Densi-
tometry of immunoblots was performed with ImageJ. All uncropped and unedited
blots are available in the Source Data. The following antibodies were used: anti-
GPX4 (1:2000, Abcam, ab125066), anti-ACSL4 (1:1000, Abcam, ab155282), anti-
TfR (1:1000, Invitrogen, H68.4), anti-FPN1 (1:1000, Eurogentec, Lìege, Belgium)
anti-ferritin (1:1000, Sigma, F5012), anti-phospho-NF-κB p65 (1:1000, Cell Sig-
nalling Technology, 3039), anti-NF-κB p65 (1:1000, Cell Signalling Technology,
8242), with anti-GAPDH (1:2000, Cell Signalling Technology, 2118) or anti-ß-actin
(1:2000, Sigma, A2066 and Abcam, ab49900) as loading control.
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Cytokine quantification. Cellular supernat ants were collected, centrifuged at 300g
for 5 min and stored at −20 °C. Cytokine quantification was performed by ELISA
(IL-6, BD Biosciences, 555240; CXCL1/KC, R&D, DY453) according to the man-
ufacturer’s protocol.
Cell viability assay. Cells were seeded on 96-well plates (2000 cells per well) and
treated with siRNA for 48 h. Cell viability was assessed by AlamarBlue turnover
(Thermo Fisher Scientific, DAL1025) according to the manufacturer’s
recommendations.
Quantification of iron uptake and release. Iron uptake and release were per-
formed as previously described62. Briefly, MODE-K IECs were silenced for 48 h
with siGpx4 or siCtrl and washed with high-glucose DMEM (1% FCS, 1% peni-
cillin/streptomycin, 25 mM HEPES). To determine non-transferrin-bound iron
uptake and release, cells were incubated with 5 µM 59 ferric chloride (Perkin Elmer,
NEZ037) for 2 h. After washing, cells were transferred to high-glucose DMEM (1%
FCS, 1% penicillin/streptomycin, 25 mM HEPES) and incubated for 1 h. Iron
uptake and release were measured with a γ counter (Perkin Elmer). Uptake and
release in CPM (counts per minute) were normalized to protein quantity as
determined by BCA Assay (Thermo Fisher Scientific, 23225).
GPX4 enzymatic activity assay. Cells were collected in lysis buffer (100 mM Tris
pH 7.6, 5 mM EDTA, 1 mM NaN3 and 0.1% peroxide-free Triton-X100). Lysates
were complemented with 0.6 U/mL glutathione reductase (Sigma, G3664), 0.2 mM
nicotinamide adenine dinucleotide phosphate hydrogen (NADPH, Sigma, N7505),
3 mM reduced glutathione (GSH, Sigma, G4251) and 200 µM of the substrate
cumene hydroperoxide (CHP, Sigma, 247502). NADPH turnover was measured on
an Infinite 200PRO reader (Tecan) at 340 nm over 10 min at 37 °C. Enzymatic
activity was calculated after subtracting absorbance decay obtained from buffer
without cell lysates by using NADPH extinction coefficient of 6220/M/cm and by
normalizing to total protein content63.
LC-MS/MS analysis. The extraction protocol and analysis of bioactive lipids by
LC-MS/MS were performed by Ambiotis SAS (Toulouse, France). Briefly cell
pellets were supplemented with methanol and spiked with deuterated internal
standards (ISTD) (PGE2-d4, 5-HETE-d8, LtB4-d4, LXA4-d5). After standing at
−20 °C for 1 h and centrifugation, supernatants were diluted with H2O and sub-
jected to solid phase extraction (SPE) on an HLB 96 well plate (Oasis). Methyl
formate-eluted lipid mediators were concentrated by a nitrogen stream evaporator
before LC-MS/MS analysis. LC-MS/MS experiment was performed on a 1290
Infinity U-HPLC system (Agilent Technologies, Santa Clara, CA, USA) mounted
with a Kinetex Biphenyl column (2.1 mm, 50 mm, 1.7 µm, Phenomenex), main-
tained at 50 °C. The U-HPLC system was coupled to a 6490 triple quadrupole MS
(Agilent Technologies), equipped with electrospray ionization source, performed in
negative ion mode. Analyses were performed in multiple reaction monitoring
detection mode by use of nitrogen as collision gas. Peak detection, integration, and
quantitative analysis were done by use of MassHunter Quantitative Analysis
Software (Agilent Technologies). Results are expressed in a quantitative manner
(i.e. pg/sample). Validation and extraction efficacy of the extraction protocol was
validated in Le Faouder et al64. Data was deposited in Mendeley (https://data.
mendeley.com, 10.17632/k9ync2kd3g.2; Data for: Dietary lipids fuel GPX4-
restricted enteritis resembling CD).
Statistics. Data are expressed as mean±standard error of mean (SEM) for all
in vivo experiments. Data derived from in vitro experimentation is presented as
box and whisker plot with median and first and third quartile (boundaries). The
whiskers represent minimal and maximal values. Results shown are of at least three
independent experiments with two technical duplicates, unless stated otherwise.
Statistical significance was tested using an unpaired two-tailed Student’s t test, a
Mann–Whitney U test, a one-way or two-way ANOVA with Bonferroni correction
or a Kruskal–Wallis test followed by Dunn’s correction as indicated in the figure
legend. Significance was considered P < 0.05. Grubbs’ Test allowed determination
and exclusion of one significant outlier in a parametric sample set. Graph Pad
Prism version 5.04 was used for statistical analysis.
Study approval. We confirm that we comply with all relevant ethical regulations
regarding the use of research animals and human study participants. Human studies
were approved by the Ethics Committee of the Medical University of Innsbruck
(UN4994) and informed consent was obtained prior to sample collection. Mouse
experiments were performed in accordance with institutional guidelines of the
Medical University of Innsbruck and following approval by federal authorities
(BMWFW-66.011/0061-WF/V/3b/2016, BMBWF-66.011/0085-V/3b/2018 and
BMBWF-66.011/0160-V/3b/2019 (Innsbruck); 55.2.2-2532-2-1043 (Erlangen)).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data of this study are available from the corresponding author upon reasonable
request. The dataset generated in this study are deposited in a publicly available platform
(https://data.mendeley.com, 10.17632/k9ync2kd3g.2; Data for: Dietary lipids fuel GPX4-
restricted enteritis resembling Crohn’s disease). The source data for Figs. 1–6 and
Supplementary Fig. S1-11 are provided in the Source Data File.
Received: 26 May 2019; Accepted: 23 March 2020;
References
1. Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking
metabolism, redox biology, and disease. Cell 171, 273–285 (2017).
2. Kagan, V. E. et al. Oxidized arachidonic and adrenic PEs navigate cells to
ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017).
3. Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress
into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab.
8, 237–248 (2008).
4. Magtanong, L., Ko, P. J. & Dixon, S. J. Emerging roles for lipids in non-
apoptotic cell death. Cell Death Differ. 23, 1099–1109 (2016).
5. Ursini, F., Maiorino, M. & Gregolin, C. The selenoenzyme phospholipid
hydroperoxide glutathione peroxidase. Biochim. Biophys. Acta 839, 62–70
(1985).
6. Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid
composition. Nat. Chem. Biol. 13, 91–98 (2017).
7. Kang, M. J. et al. A novel arachidonate-preferring acyl-CoA synthetase is
present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc. Natl
Acad. Sci. USA 94, 2880–2884 (1997).
8. Chen, L., Hambright, W. S., Na, R. & Ran, Q. Ablation of the ferroptosis
inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron
degeneration and paralysis. J. Biol. Chem. 290, 28097–28106 (2015).
9. Sengupta, A. et al. Targeted disruption of glutathione peroxidase 4 in mouse
skin epithelial cells impairs postnatal hair follicle morphogenesis that is
partially rescued through inhibition of COX-2. J. Investigative Dermatol. 133,
1731–1741 (2013).
10. Linkermann, A. et al. Synchronized renal tubular cell death involves
ferroptosis. Proc. Natl Acad. Sci. USA 111, 16836–16841 (2014).
11. Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4
triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).
12. Wenzel, S. E. et al. PEBP1 wardens ferroptosis by enabling lipoxygenase
generation of lipid death signals. Cell 171, 628–641 e626 (2017).
13. Alvarez, S. W. et al. NFS1 undergoes positive selection in lung tumours and
protects cells from ferroptosis. Nature 551, 639–643 (2017).
14. Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to
GPX4 inhibition. Nature 551, 247–250 (2017).
15. Uhlig, H. H. & Powrie, F. Translating immunology into therapeutic concepts
for inflammatory bowel disease. Annu. Rev. Immunol. 36, 755–781 (2018).
16. Chu, H. et al. Gene-microbiota interactions contribute to the pathogenesis of
inflammatory bowel disease. Science 352, 1116–1120 (2016).
17. Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont
expansion and colitis in Il10-/- mice. Nature 487, 104–108 (2012).
18. Chassaing, B. et al. Dietary emulsifiers impact the mouse gut microbiota
promoting colitis and metabolic syndrome. Nature 519, 92–96 (2015).
19. Patterson, E., Wall, R., Fitzgerald, G. F., Ross, R. P. & Stanton, C. Health
implications of high dietary omega-6 polyunsaturated fatty acids. J. Nutr.
Metab. 2012, 539426 (2012).
20. de Silva, P. S. et al. An association between dietary arachidonic acid, measured in
adipose tissue, and ulcerative colitis. Gastroenterology 139, 1912–1917 (2010).
21. Nishida, T. et al. Increased arachidonic acid composition of phospholipids in
colonic mucosa from patients with active ulcerative colitis. Gut 28, 1002–1007
(1987).
22. Ungaro, F., Rubbino, F., Danese, S. & D’Alessio, S. Actors and factors in the
resolution of intestinal inflammation: lipid mediators as a new approach to
therapy in inflammatory bowel diseases. Front Immunol. 8, 1331 (2017).
23. Jostins, L. et al. Host-microbe interactions have shaped the genetic
architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
24. Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation.
Nature 517, 311–320 (2015).
25. Cummings, R. J. et al. Different tissue phagocytes sample apoptotic cells to
direct distinct homeostasis programs. Nature 539, 565–569 (2016).
26. Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and
targeting genomes. Nat. Biotechnol. 32, 347–355 (2014).
27. Yoo, S. E. et al. Gpx4 ablation in adult mice results in a lethal phenotype
accompanied by neuronal loss in brain. Free Radic. Biol. Med 52, 1820–1827
(2012).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15646-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1775 | https://doi.org/10.1038/s41467-020-15646-6 | www.nature.com/naturecommunications 13
28. Madison, B. B. et al. Cis elements of the villin gene control expression in
restricted domains of the vertical (crypt) and horizontal (duodenum, cecum)
axes of the intestine. J. Biol. Chem. 277, 33275–33283 (2002).
29. Canli, O. et al. Myeloid cell-derived reactive oxygen species induce epithelial
mutagenesis. Cancer Cell 32, 869–883 e865 (2017).
30. Yang, W. S. et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases
drives ferroptosis. Proc. Natl Acad. Sci. USA 113, E4966–E4975 (2016).
31. Gasche, C. et al. Ferric maltol is effective in correcting iron deficiency anemia
in patients with inflammatory bowel disease: results from a phase-3 clinical
trial program. Inflamm. Bowel Dis. 21, 579–588 (2015).
32. Yang, Q. et al. Dietary intake of n-3 PUFAs modifies the absorption,
distribution and bioavailability of fatty acids in the mouse gastrointestinal
tract. Lipids Health Dis. 16, 10 (2017).
33. Muckenthaler, M. U., Rivella, S., Hentze, M. W. & Galy, B. A red carpet for
iron metabolism. Cell 168, 344–361 (2017).
34. Node, K. et al. Anti-inflammatory properties of cytochrome P450
epoxygenase-derived eicosanoids. Science (New York, NY) 285, 1276–1279
(1999).
35. Ganesan, B., Brothersen, C. & McMahon, D. J. Fortification of foods with
omega-3 polyunsaturated fatty acids. Crit. Rev. Food Sci. Nutr. 54, 98–114
(2014).
36. Simopoulos, A. P. An Increase in the Omega-6/Omega-3 fatty acid ratio
increases the risk for obesity. Nutrients 8, 128 (2016).
37. Hou, J. K., Abraham, B. & El-Serag, H. Dietary intake and risk of developing
inflammatory bowel disease: a systematic review of the literature. Am. J.
Gastroenterol. 106, 563–573 (2011).
38. Lev-Tzion, R., Griffiths, A. M., Leder, O. & Turner, D. Omega 3 fatty acids
(fish oil) for maintenance of remission in Crohn’s disease. The Cochrane
database of systematic reviews, CD006320, https://doi.org/10.1002/14651858.
CD006320.pub4 (2014).
39. Hull, M. A. et al. Eicosapentaenoic acid and aspirin, alone and in combination,
for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a
multicentre, randomised, double-blind, placebo-controlled, 2 x 2 factorial trial.
Lancet 392, 2583–2594 (2018).
40. Gorard, D. A. et al. Initial response and subsequent course of Crohn’s disease
treated with elemental diet or prednisolone. Gut 34, 1198–1202 (1993).
41. Yamamoto, T., Nakahigashi, M., Umegae, S., Kitagawa, T. & Matsumoto, K.
Impact of elemental diet on mucosal inflammation in patients with active
Crohn’s disease: cytokine production and endoscopic and histological
findings. Inflamm. Bowel Dis. 11, 580–588 (2005).
42. Kurashima, Y. & Kiyono, H. Mucosal ecological network of epithelium and
immune cells for gut homeostasis and tissue healing. Annu. Rev. Immunol. 35,
119–147 (2017).
43. Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation.
Nat. Rev. Immunol. 15, 511–523 (2015).
44. Moor, A. E. et al. Spatial reconstruction of single enterocytes uncovers broad
zonation along the Intestinal Villus Axis. Cell 175, 1156–1167 e1115 (2018).
45. Belluzzi, A. et al. Effect of an enteric-coated fish-oil preparation on relapses in
Crohn’s disease. N. Engl. J. Med 334, 1557–1560 (1996).
46. Feagan, B. G. et al. Omega-3 free fatty acids for the maintenance of remission
in Crohn disease: the EPIC Randomized Controlled Trials. Jama 299,
1690–1697 (2008).
47. Turner, D., Shah, P. S., Steinhart, A. H., Zlotkin, S. & Griffiths, A. M.
Maintenance of remission in inflammatory bowel disease using omega-3 fatty
acids (fish oil): a systematic review and meta-analyses. Inflamm. bowel Dis. 17,
336–345 (2011).
48. Yant, L. J. et al. The selenoprotein GPX4 is essential for mouse development
and protects from radiation and oxidative damage insults. Free Radic. Biol.
Med 34, 496–502 (2003).
49. Maiorino, M., Roveri, A., Gregolin, C. & Ursini, F. Different effects of Triton
X-100, deoxycholate, and fatty acids on the kinetics of glutathione peroxidase
and phospholipid hydroperoxide glutathione peroxidase. Arch. Biochem
Biophys. 251, 600–605 (1986).
50. Garreta, A. et al. Structure and interaction with phospholipids of a prokaryotic
lipoxygenase from Pseudomonas aeruginosa. FASEB J. 27, 4811–4821
(2013).
51. Grootjans, J., Kaser, A., Kaufman, R. J. & Blumberg, R. S. The unfolded
protein response in immunity and inflammation. Nat. Rev. Immunol. 16,
469–484 (2016).
52. Bowie, A. G., Moynagh, P. N. & O’Neill, L. A. Lipid peroxidation is involved
in the activation of NF-kappaB by tumor necrosis factor but not interleukin-1
in the human endothelial cell line ECV304. Lack of involvement of H2O2 in
NF-kappaB activation by either cytokine in both primary and transformed
endothelial cells. J. Biol. Chem. 272, 25941–25950 (1997).
53. Mills, E. L. et al. Succinate dehydrogenase supports metabolic repurposing of
mitochondria to drive inflammatory macrophages. Cell 167, 457–470 e413
(2016).
54. Ip, W. K. E., Hoshi, N., Shouval, D. S., Snapper, S. & Medzhitov, R. Anti-
inflammatory effect of IL-10 mediated by metabolic reprogramming of
macrophages. Science 356, 513–519 (2017).
55. von Moltke, J. et al. Rapid induction of inflammatory lipid mediators by the
inflammasome in vivo. Nature 490, 107–111 (2012).
56. Garrett, W. S. et al. Communicable ulcerative colitis induced by T-bet
deficiency in the innate immune system. Cell 131, 33–45 (2007).
57. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide
libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
58. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro
without a mesenchymal niche. Nature 459, 262–265 (2009).
59. Adolph, T. E. et al. Paneth cells as a site of origin for intestinal inflammation.
Nature 503, 272–276 (2013).
60. Platt, A. M., Bain, C. C., Bordon, Y., Sester, D. P. & Mowat, A. M. An
independent subset of TLR expressing CCR2-dependent macrophages
promotes colonic inflammation. J. Immunol. 184, 6843–6854 (2010).
61. Gerner, R. R. et al. NAD metabolism fuels human and mouse intestinal
inflammation. Gut https://doi.org/10.1136/gutjnl-2017-314241 (2017).
62. Ludwiczek, S., Aigner, E., Theurl, I. & Weiss, G. Cytokine-mediated
regulation of iron transport in human monocytic cells. Blood 101, 4148–4154
(2003).
63. Brault, C. et al. Glutathione peroxidase 4 is reversibly induced by HCV to
control lipid peroxidation and to increase virion infectivity. Gut 65, 144–154
(2016).
64. Le Faouder, P. et al. LC-MS/MS method for rapid and concomitant
quantification of pro-inflammatory and pro-resolving polyunsaturated fatty
acid metabolites. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 932,
123–133 (2013).
Acknowledgements
The authors are grateful for the support received from the Austrian Science Fund (FWF,
P 29379-B28), the Tyrolean Science Fund (TWF, 0404/1812), the Austrian Society of
Gastroenterology and Hepatology (ÖGGH) and the European Crohn’s and Colitis
Organisation (ECCO) (to T.E.A.). We thank the Excellence Initiative (Competence
Centers for Excellent Technologies—COMET) of the Austrian Research Promotion
Agency FFG: Research Center of Excellence in Vascular Ageing Tyrol, VASCage
(K-Project Nr. 843536) funded by BMVIT, BMWFW, Wirtschaftsagentur Wien and
Standortagentur Tirol for their financial support (to H.T.). This work was further sup-
ported by the German Funding Agency (DFG) through the CRC1182 (C2 to F.S. & P.R.),
the excellence initiative EXC306 (to P.R.) and EXS2167 (to P.R.). We thank the German
Funding Agency (DFG) through TRR241 (A03 to C.B.) and SFB1181 (C05 to C.B.). We
appreciate the support of the Christian Doppler Research Foundation and the Austrian
Federal Ministry of Science, Research and Economy and the National Foundation for
Research, Technology and Development (to A.R.M and G.W.). We thank Cornelia
Wiedner Stiftung and Deutsche Arbeitsgemeinschaft für chronisch entzündliche Dar-
merkrankungen (DACED) for financial support (to T.E.A). Finally, we thank Karina
Greve and the IKMB NGS lab for excellent technical support.
Author contributions
H.T. and T.E.A. contributed equally to this work. L.M. and F.G. designed, performed,
and analyzed most experiments and helped prepare the manuscript together with T.G.,
J.S., I.R. L.N., G.W.H., B.R., K.K., N.P., P.T., R.H., D.H., M.S., C.F., R.R.G., and B.E. G.O.
and S.S. provided pathology expertise. M.K. helped with LC-MS/MS methodology. Q.R.
and C.B. provided an experimental tool. R.K., M.E., and H.Z. provided access to clinical
samples. F.S., P.R., H.Z., A.R.M., I.T., G.W., and A.K. helped develop the project. H.T.
and T.E.A coordinated the project and prepared the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-15646-6.
Correspondence and requests for materials should be addressed to T.E.A.
Peer review information Nature Communications thanks Vidya Velagapudi and the
other anonymous reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15646-6
14 NATURE COMMUNICATIONS |         (2020) 11:1775 | https://doi.org/10.1038/s41467-020-15646-6 | www.nature.com/naturecommunications
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15646-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1775 | https://doi.org/10.1038/s41467-020-15646-6 | www.nature.com/naturecommunications 15
